Pharmacyclics Inc (PCYC) 256.59 $PCYC
Shares of PCYC Up 74.7% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Apr 24, 9:46AM CDT
SmarTrend identified an Uptrend for Pharmacyclics (NASDAQ
CYC) on January 13th, 2015 at $147.27. In approximately 3 months, Pharmacyclics has returned 74.73% as of today's recent price of $257.33.
PCYC: 256.59 (-0.51)
Humira Propels AbbVie Inc. to a Solid First Quarter
Keith Speights, The Motley Fool - Motley Fool - Thu Apr 23, 10:34AM CDT
Source: AbbVie. This year has been somewhat lackluster so far for AbbVie shareholders. The stock was down as much as 15% before regaining some momentum in recent weeks. The drugmaker announced first-quarter financial results before the market...
PCYC: 256.59 (-0.51), ABBV: 66.07 (+1.82)
AbbVie Beats Earnings on Humira and HCV Sales, Ups View - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Apr 23, 10:18AM CDT
AbbVie (ABBV) surpassed expectations on the back of Humira sales and contribution from Viekira.
BIIB: 401.71 (-28.57), PCYC: 256.59 (-0.51), SHPG: 255.11 (-0.26), ABBV: 66.07 (+1.82)
Forget Google: 5 Top Stocks With Earnings Thursday
at Investor's Business Daily - Wed Apr 22, 6:31PM CDT
Tech titan Google (GOOGL) will make headlines with its quarterly earnings after the close on Thursday. But Google's growth is sluggish and the stock is lackluster. Check out these five stocks with better performance than the search giant, including...
AMZN: 445.10 (+55.11), PCYC: 256.59 (-0.51), MO: 52.07 (-0.28), ALK: 68.30 (+1.96), LUV: 43.49 (+0.23), SBUX: 51.84 (+2.41), GILD: 103.69 (-1.52), ALXN: 180.08 (-4.50), GM: 35.59 (-0.33), GOOGL: 573.66 (+16.20), ABBV: 66.07 (+1.82), PG: 81.00 (+0.05), MSFT: 47.87 (+4.53), DOW: 51.12 (+0.12)
Gilead Sciences Vs. AbbVie: Which Is A Better Buy?
Mycroft - at Seeking Alpha - Wed Apr 22, 7:49AM CDT
JNJ: 101.08 (+0.62), ABT: 48.32 (-0.14), PCYC: 256.59 (-0.51), GILD: 103.69 (-1.52), SHPG: 255.11 (-0.26), ABBV: 66.07 (+1.82)
Pharmacyclics Announces Positive Results on Imbruvica - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 4:54PM CDT
Pharmacyclics (PCYC) announced positive long-term follow-up data on Imbruvica.
BIIB: 401.71 (-28.57), JNJ: 101.08 (+0.62), PCYC: 256.59 (-0.51), ABBV: 66.07 (+1.82)
Is AbbVie (ABBV) Set to Top 1Q Earnings on Humira & HCV? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 2:14PM CDT
Will AbbVie (ABBV) surpass earnings expectations in 1Q on the back of strong Humira and Viekira sales?
BIIB: 401.71 (-28.57), PCYC: 256.59 (-0.51), IMGN: 9.96 (-0.29), ABBV: 66.07 (+1.82)
Forget Gilead (GILD), Buy These Impressive Biotech Stocks Instead - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 8:09AM CDT
It's time we overlooked Gilead for some biotech growth stocks.
BIIB: 401.71 (-28.57), JNJ: 101.08 (+0.62), ESRX: 87.34 (+0.45), PCYC: 256.59 (-0.51), GILD: 103.69 (-1.52), ANTH: 5.20 (+0.31), GERN: 4.30 (-0.03), ABBV: 66.07 (+1.82)
Stock Updates on Biotech -- Celgene, Amgen, PDL BioPharma, Amarin, and Pharmacyclics
PR Newswire - Tue Apr 21, 7:30AM CDT
Editor Note: For more information about this release, please scroll to bottom.
PCYC: 256.59 (-0.51), AMRN: 2.33 (-0.10), AMGN: 167.91 (-1.26), PDLI: 7.02 (-0.09), CELG: 118.71 (+2.62), CELGZ: 2.76 (-0.12)
Ibrutinib (IMBRUVICA®) Improves Outcomes for Pancreatic Ductal Adenocarcinoma in Mouse Models
PR Newswire - Mon Apr 20, 8:00AM CDT
Ibrutinib (IMBRUVICA®) data presented yesterday by Pharmacyclics, Inc. (NASDAQ: PCYC) at the American Association for Cancer Research (AACR) Annual Meeting suggest that ibrutinib may be an effective therapeutic option for pancreatic ductal adenocarcinoma (PDAC), as shown in both a transgenic mouse model and an in-vivo model of patient-derived xenograft (PDX) mice (grafts of tissue taken from a pancreatic cancer patient and grafted into a mouse).1 These early, pre-clinical data show ibrutinib was associated with potent anti-fibrotic activity and longer survival in the treated mice. PDAC is a type of pancreatic cancer that is typically characterized by a fibro-inflammatory reaction, which makes PDAC a difficult disease to treat with current therapies. These data were also published in the April 15th edition of Cancer Research. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, Inc.
PCYC: 256.59 (-0.51)
IMBRUVICA® (ibrutinib) Longer-Term Follow-Up Data Demonstrate Durable Responses, Including Complete Responses, in Patients with Chronic Lymphocytic Leukemia (CLL)
PR Newswire - Mon Apr 20, 7:45AM CDT
Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that IMBRUVICA® (ibrutinib) follow-up data in treatment-naive (TN) and relapsed/refractory (R/R) patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL or SLL, respectively) demonstrated that, with up to 45 months of follow-up, the 94 patients (27 TN and 67 R/R) who received IMBRUVICA 420 mg experienced a 91% overall response rate (ORR) and 14% of all patients achieved a complete response (CR) (26% TN, 9% R/R). These data are an analysis of outcomes from the Phase I/IIb study (PCYC-1102) and the ongoing extension study (PCYC-1103) and were presented in an oral presentation yesterday at the American Association of Cancer Research (AACR) Annual Meeting in Philadelphia, PA by Steven Coutre, M.D., Professor of Medicine, Stanford University School of Medicine, Stanford, CA. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, Inc.
PCYC: 256.59 (-0.51)
AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc.
PR Newswire - Fri Apr 17, 3:47PM CDT
AbbVie Inc. ("AbbVie"
(NYSE / CHX / Euronext Paris / SIX: ABBV) today announced that it has extended the expiration of its exchange offer to acquire all of the outstanding shares of common stock of Pharmacyclics, Inc. to 5 p.m., New York City time, on May 1, 2015.
PCYC: 256.59 (-0.51), ABBV: 66.07 (+1.82)
Johnson & Johnson's Earnings: What You Need to Know
Todd Campbell and Michael Douglass, The Motley Fool - Motley Fool - Fri Apr 17, 9:01AM CDT
Healthcare giant Johnson & Johnson is one of the first multinationals to report earnings this quarter. While clearly instructive for current and potential J&J investors, the report also offers some insight into the broader sector and the...
MDVN: 131.01 (-1.50), JNJ: 101.08 (+0.62), PCYC: 256.59 (-0.51)
4 Big Biopharma Deals We Might See In 2015
Sy Mukherjee - Seeking Alpha - Thu Apr 16, 1:29PM CDT
In 2000, UK-based Glaxo Wellcome joined forces with SmithKline Beecham in a $74 billion merger that birthed the global pharma giant GlaxoSmithKline (NYSE: GSK ). It was, far and away, the biggest biopharma deal of the year. What a difference 14...
BMRN: 120.28 (-2.67), PCYC: 256.59 (-0.51), PFE: 35.27 (-0.09), BMY: 65.80 (-0.20), GSK: 46.59 (+0.28), HSP: 87.61 (-0.05), CELG: 118.71 (+2.62), SGEN: 37.14 (-0.36), GILD: 103.69 (-1.52), SHPG: 255.11 (-0.26), AZN: 71.79 (-1.34), JAZZ: 189.42 (+0.33), MRK: 57.60 (+0.09), ABBV: 66.07 (+1.82)
Johnson & Johnson's Earnings: The Good, The Bad and The Ugly
George Budwell, The Motley Fool - Motley Fool - Thu Apr 16, 10:59AM CDT
After a stellar 2014, Johnson & Johnson 's stock has lagged behind the broader market this year: To gain some insight into this top healthcare stock's weakness so far in 2015, let's dig into the company's first-quarter earnings,...
ACHC: 72.60 (+0.22), JNJ: 101.08 (+0.62), PCYC: 256.59 (-0.51), ISIS: 66.37 (-1.38), SGEN: 37.14 (-0.36), GILD: 103.69 (-1.52), PFG: 51.62 (+0.31), ABBV: 66.07 (+1.82), PBYI: 222.10 (-6.35)
3 Biotech Stocks Under $10 with Amazing Growth Prospects - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 15, 9:52AM CDT
The biotech sector is witnessing changing dynamics with the focus shifting from large caps to smaller companies with high growth potential.
JNJ: 101.08 (+0.62), ESRX: 87.34 (+0.45), PCYC: 256.59 (-0.51), GILD: 103.69 (-1.52), ANTH: 5.20 (+0.31), CYTX: 0.99 (+0.01), GERN: 4.30 (-0.03), PFE: 35.27 (-0.09), AMGN: 167.91 (-1.26), ABBV: 66.07 (+1.82), HSP: 87.61 (-0.05), NVS: 104.28 (-1.22)
J&J Earnings Beat Estimates; Guidance Mixed
at Investor's Business Daily - Tue Apr 14, 4:48PM CDT
Johnson & Johnson kicked off health care's Q1 earnings season with a report that pointed to solid fundamentals but punishing foreign-exchange (FX) headwinds. On a reported basis, Johnson & Johnson's (JNJ) sales dropped 4.1% from the year-earlier...
JNJ: 101.08 (+0.62), PCYC: 256.59 (-0.51), GILD: 103.69 (-1.52), AZN: 71.79 (-1.34), ABBV: 66.07 (+1.82)
Chinese Stocks Lead Stock Market Higher
at Investor's Business Daily - Mon Apr 13, 11:03AM CDT
Stocks held early gains near the noon hour Monday as Chinese ADRs continue to show strength after a string of breakouts last week. The Nasdaq rose 0.5% while the S&P 500 and the Dow Jones industrial average gained 0.2%. Volume was tracking slightly...
NOAH: 33.79 (+0.63), PCYC: 256.59 (-0.51), APOG: 53.48 (+0.55), ABBV: 66.07 (+1.82), CMGE: 21.58 (-0.22), FXI: 51.92 (+0.07)
Shares of PCYC Up 74.7% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Apr 24, 9:46AM CDT
SmarTrend identified an Uptrend for Pharmacyclics (NASDAQ
CYC) on January 13th, 2015 at $147.27. In approximately 3 months, Pharmacyclics has returned 74.73% as of today's recent price of $257.33. PCYC: 256.59 (-0.51)
Humira Propels AbbVie Inc. to a Solid First Quarter
Keith Speights, The Motley Fool - Motley Fool - Thu Apr 23, 10:34AM CDT
Source: AbbVie. This year has been somewhat lackluster so far for AbbVie shareholders. The stock was down as much as 15% before regaining some momentum in recent weeks. The drugmaker announced first-quarter financial results before the market...
PCYC: 256.59 (-0.51), ABBV: 66.07 (+1.82)
AbbVie Beats Earnings on Humira and HCV Sales, Ups View - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Apr 23, 10:18AM CDT
AbbVie (ABBV) surpassed expectations on the back of Humira sales and contribution from Viekira.
BIIB: 401.71 (-28.57), PCYC: 256.59 (-0.51), SHPG: 255.11 (-0.26), ABBV: 66.07 (+1.82)
Forget Google: 5 Top Stocks With Earnings Thursday
at Investor's Business Daily - Wed Apr 22, 6:31PM CDT
Tech titan Google (GOOGL) will make headlines with its quarterly earnings after the close on Thursday. But Google's growth is sluggish and the stock is lackluster. Check out these five stocks with better performance than the search giant, including...
AMZN: 445.10 (+55.11), PCYC: 256.59 (-0.51), MO: 52.07 (-0.28), ALK: 68.30 (+1.96), LUV: 43.49 (+0.23), SBUX: 51.84 (+2.41), GILD: 103.69 (-1.52), ALXN: 180.08 (-4.50), GM: 35.59 (-0.33), GOOGL: 573.66 (+16.20), ABBV: 66.07 (+1.82), PG: 81.00 (+0.05), MSFT: 47.87 (+4.53), DOW: 51.12 (+0.12)
Gilead Sciences Vs. AbbVie: Which Is A Better Buy?
Mycroft - at Seeking Alpha - Wed Apr 22, 7:49AM CDT
JNJ: 101.08 (+0.62), ABT: 48.32 (-0.14), PCYC: 256.59 (-0.51), GILD: 103.69 (-1.52), SHPG: 255.11 (-0.26), ABBV: 66.07 (+1.82)
Pharmacyclics Announces Positive Results on Imbruvica - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 4:54PM CDT
Pharmacyclics (PCYC) announced positive long-term follow-up data on Imbruvica.
BIIB: 401.71 (-28.57), JNJ: 101.08 (+0.62), PCYC: 256.59 (-0.51), ABBV: 66.07 (+1.82)
Is AbbVie (ABBV) Set to Top 1Q Earnings on Humira & HCV? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 2:14PM CDT
Will AbbVie (ABBV) surpass earnings expectations in 1Q on the back of strong Humira and Viekira sales?
BIIB: 401.71 (-28.57), PCYC: 256.59 (-0.51), IMGN: 9.96 (-0.29), ABBV: 66.07 (+1.82)
Forget Gilead (GILD), Buy These Impressive Biotech Stocks Instead - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 8:09AM CDT
It's time we overlooked Gilead for some biotech growth stocks.
BIIB: 401.71 (-28.57), JNJ: 101.08 (+0.62), ESRX: 87.34 (+0.45), PCYC: 256.59 (-0.51), GILD: 103.69 (-1.52), ANTH: 5.20 (+0.31), GERN: 4.30 (-0.03), ABBV: 66.07 (+1.82)
Stock Updates on Biotech -- Celgene, Amgen, PDL BioPharma, Amarin, and Pharmacyclics
PR Newswire - Tue Apr 21, 7:30AM CDT
Editor Note: For more information about this release, please scroll to bottom.
PCYC: 256.59 (-0.51), AMRN: 2.33 (-0.10), AMGN: 167.91 (-1.26), PDLI: 7.02 (-0.09), CELG: 118.71 (+2.62), CELGZ: 2.76 (-0.12)
Ibrutinib (IMBRUVICA®) Improves Outcomes for Pancreatic Ductal Adenocarcinoma in Mouse Models
PR Newswire - Mon Apr 20, 8:00AM CDT
Ibrutinib (IMBRUVICA®) data presented yesterday by Pharmacyclics, Inc. (NASDAQ: PCYC) at the American Association for Cancer Research (AACR) Annual Meeting suggest that ibrutinib may be an effective therapeutic option for pancreatic ductal adenocarcinoma (PDAC), as shown in both a transgenic mouse model and an in-vivo model of patient-derived xenograft (PDX) mice (grafts of tissue taken from a pancreatic cancer patient and grafted into a mouse).1 These early, pre-clinical data show ibrutinib was associated with potent anti-fibrotic activity and longer survival in the treated mice. PDAC is a type of pancreatic cancer that is typically characterized by a fibro-inflammatory reaction, which makes PDAC a difficult disease to treat with current therapies. These data were also published in the April 15th edition of Cancer Research. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, Inc.
PCYC: 256.59 (-0.51)
IMBRUVICA® (ibrutinib) Longer-Term Follow-Up Data Demonstrate Durable Responses, Including Complete Responses, in Patients with Chronic Lymphocytic Leukemia (CLL)
PR Newswire - Mon Apr 20, 7:45AM CDT
Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that IMBRUVICA® (ibrutinib) follow-up data in treatment-naive (TN) and relapsed/refractory (R/R) patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL or SLL, respectively) demonstrated that, with up to 45 months of follow-up, the 94 patients (27 TN and 67 R/R) who received IMBRUVICA 420 mg experienced a 91% overall response rate (ORR) and 14% of all patients achieved a complete response (CR) (26% TN, 9% R/R). These data are an analysis of outcomes from the Phase I/IIb study (PCYC-1102) and the ongoing extension study (PCYC-1103) and were presented in an oral presentation yesterday at the American Association of Cancer Research (AACR) Annual Meeting in Philadelphia, PA by Steven Coutre, M.D., Professor of Medicine, Stanford University School of Medicine, Stanford, CA. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, Inc.
PCYC: 256.59 (-0.51)
AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc.
PR Newswire - Fri Apr 17, 3:47PM CDT
AbbVie Inc. ("AbbVie"
(NYSE / CHX / Euronext Paris / SIX: ABBV) today announced that it has extended the expiration of its exchange offer to acquire all of the outstanding shares of common stock of Pharmacyclics, Inc. to 5 p.m., New York City time, on May 1, 2015. PCYC: 256.59 (-0.51), ABBV: 66.07 (+1.82)
Johnson & Johnson's Earnings: What You Need to Know
Todd Campbell and Michael Douglass, The Motley Fool - Motley Fool - Fri Apr 17, 9:01AM CDT
Healthcare giant Johnson & Johnson is one of the first multinationals to report earnings this quarter. While clearly instructive for current and potential J&J investors, the report also offers some insight into the broader sector and the...
MDVN: 131.01 (-1.50), JNJ: 101.08 (+0.62), PCYC: 256.59 (-0.51)
4 Big Biopharma Deals We Might See In 2015
Sy Mukherjee - Seeking Alpha - Thu Apr 16, 1:29PM CDT
In 2000, UK-based Glaxo Wellcome joined forces with SmithKline Beecham in a $74 billion merger that birthed the global pharma giant GlaxoSmithKline (NYSE: GSK ). It was, far and away, the biggest biopharma deal of the year. What a difference 14...
BMRN: 120.28 (-2.67), PCYC: 256.59 (-0.51), PFE: 35.27 (-0.09), BMY: 65.80 (-0.20), GSK: 46.59 (+0.28), HSP: 87.61 (-0.05), CELG: 118.71 (+2.62), SGEN: 37.14 (-0.36), GILD: 103.69 (-1.52), SHPG: 255.11 (-0.26), AZN: 71.79 (-1.34), JAZZ: 189.42 (+0.33), MRK: 57.60 (+0.09), ABBV: 66.07 (+1.82)
Johnson & Johnson's Earnings: The Good, The Bad and The Ugly
George Budwell, The Motley Fool - Motley Fool - Thu Apr 16, 10:59AM CDT
After a stellar 2014, Johnson & Johnson 's stock has lagged behind the broader market this year: To gain some insight into this top healthcare stock's weakness so far in 2015, let's dig into the company's first-quarter earnings,...
ACHC: 72.60 (+0.22), JNJ: 101.08 (+0.62), PCYC: 256.59 (-0.51), ISIS: 66.37 (-1.38), SGEN: 37.14 (-0.36), GILD: 103.69 (-1.52), PFG: 51.62 (+0.31), ABBV: 66.07 (+1.82), PBYI: 222.10 (-6.35)
3 Biotech Stocks Under $10 with Amazing Growth Prospects - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 15, 9:52AM CDT
The biotech sector is witnessing changing dynamics with the focus shifting from large caps to smaller companies with high growth potential.
JNJ: 101.08 (+0.62), ESRX: 87.34 (+0.45), PCYC: 256.59 (-0.51), GILD: 103.69 (-1.52), ANTH: 5.20 (+0.31), CYTX: 0.99 (+0.01), GERN: 4.30 (-0.03), PFE: 35.27 (-0.09), AMGN: 167.91 (-1.26), ABBV: 66.07 (+1.82), HSP: 87.61 (-0.05), NVS: 104.28 (-1.22)
J&J Earnings Beat Estimates; Guidance Mixed
at Investor's Business Daily - Tue Apr 14, 4:48PM CDT
Johnson & Johnson kicked off health care's Q1 earnings season with a report that pointed to solid fundamentals but punishing foreign-exchange (FX) headwinds. On a reported basis, Johnson & Johnson's (JNJ) sales dropped 4.1% from the year-earlier...
JNJ: 101.08 (+0.62), PCYC: 256.59 (-0.51), GILD: 103.69 (-1.52), AZN: 71.79 (-1.34), ABBV: 66.07 (+1.82)
Chinese Stocks Lead Stock Market Higher
at Investor's Business Daily - Mon Apr 13, 11:03AM CDT
Stocks held early gains near the noon hour Monday as Chinese ADRs continue to show strength after a string of breakouts last week. The Nasdaq rose 0.5% while the S&P 500 and the Dow Jones industrial average gained 0.2%. Volume was tracking slightly...
NOAH: 33.79 (+0.63), PCYC: 256.59 (-0.51), APOG: 53.48 (+0.55), ABBV: 66.07 (+1.82), CMGE: 21.58 (-0.22), FXI: 51.92 (+0.07)
